Lawrence Korducki
Boehringer Ingelheim (United States)(US)
Publications by Year
Research Areas
Chronic Obstructive Pulmonary Disease (COPD) Research, Respiratory Support and Mechanisms, Asthma and respiratory diseases, Respiratory and Cough-Related Research, Pulmonary Hypertension Research and Treatments
Most-Cited Works
- → Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)(2015)322 cited
- → Effect of Bronchodilation, Exercise Training, and Behavior Modification on Symptoms and Physical Activity in Chronic Obstructive Pulmonary Disease(2018)101 cited
- → Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies(2014)95 cited
- → Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease(2002)91 cited
- → Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies(2014)71 cited
- → Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis(2015)55 cited
- → Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting β2-agonist, in patients with mild asthma(2009)43 cited
- → The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies(2014)40 cited
- → Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design(2016)39 cited
- → One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2–4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis(2015)35 cited